» Articles » PMID: 35982257

Cognitive Deficits, Clinical Variables, and White Matter Microstructure in Schizophrenia: a Multisite Harmonization Study

Abstract

Cognitive deficits are among the best predictors of real-world functioning in schizophrenia. However, our understanding of how cognitive deficits relate to neuropathology and clinical presentation over the disease lifespan is limited. Here, we combine multi-site, harmonized cognitive, imaging, demographic, and clinical data from over 900 individuals to characterize a) cognitive deficits across the schizophrenia lifespan and b) the association between cognitive deficits, clinical presentation, and white matter (WM) microstructure. Multimodal harmonization was accomplished using T-scores for cognitive data, previously reported standardization methods for demographic and clinical data, and an established harmonization method for imaging data. We applied t-tests and correlation analysis to describe cognitive deficits in individuals with schizophrenia. We then calculated whole-brain WM fractional anisotropy (FA) and utilized regression-mediation analyses to model the association between diagnosis, FA, and cognitive deficits. We observed pronounced cognitive deficits in individuals with schizophrenia (p < 0.006), associated with more positive symptoms and medication dosage. Regression-mediation analyses showed that WM microstructure mediated the association between schizophrenia and language/processing speed/working memory/non-verbal memory. In addition, processing speed mediated the influence of diagnosis and WM microstructure on the other cognitive domains. Our study highlights the critical role of cognitive deficits in schizophrenia. We further show that WM is crucial when trying to understand the role of cognitive deficits, given that it explains the association between schizophrenia and cognitive deficits (directly and via processing speed).

Citing Articles

Addressing brain metabolic connectivity in treatment-resistant schizophrenia: a novel graph theory-driven application of F-FDG-PET with antipsychotic dose correction.

De Simone G, Iasevoli F, Barone A, Gaudieri V, Cuocolo A, Ciccarelli M Schizophrenia (Heidelb). 2024; 10(1):116.

PMID: 39702476 PMC: 11659424. DOI: 10.1038/s41537-024-00535-4.


Improved patient identification by incorporating symptom severity in deep learning using neuroanatomic images in first episode schizophrenia.

Zhang W, Wang L, Wu X, Yao L, Yi Z, Yin H Neuropsychopharmacology. 2024; 50(3):531-539.

PMID: 39506100 PMC: 11735835. DOI: 10.1038/s41386-024-02021-y.


A diffusion MRI tractography atlas for concurrent white matter mapping across Eastern and Western populations.

Li Y, Zhang W, Wu Y, Yin L, Zhu C, Chen Y Sci Data. 2024; 11(1):787.

PMID: 39019877 PMC: 11255335. DOI: 10.1038/s41597-024-03624-2.


The pathobiology of psychomotor slowing in psychosis: altered cortical excitability and connectivity.

Lefebvre S, Gehrig G, Nadesalingam N, Nuoffer M, Kyrou A, Wuthrich F Brain. 2024; 147(4):1423-1435.

PMID: 38537253 PMC: 10994557. DOI: 10.1093/brain/awad395.


Association of homocysteine with white matter dysconnectivity in schizophrenia.

Tabata K, Son S, Miyata J, Toriumi K, Miyashita M, Suzuki K Schizophrenia (Heidelb). 2024; 10(1):39.

PMID: 38509166 PMC: 10954654. DOI: 10.1038/s41537-024-00458-0.


References
1.
Mueser K, McGurk S . Schizophrenia. Lancet. 2004; 363(9426):2063-72. DOI: 10.1016/S0140-6736(04)16458-1. View

2.
Mitchell A, Dinan T . Schizophrenia: a multisystem disease?. J Psychopharmacol. 2010; 24(4 Suppl):5-7. PMC: 2951587. DOI: 10.1177/1359786810382059. View

3.
Mesholam-Gately R, Giuliano A, Goff K, Faraone S, Seidman L . Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009; 23(3):315-36. DOI: 10.1037/a0014708. View

4.
Heinrichs R, Zakzanis K . Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998; 12(3):426-45. DOI: 10.1037//0894-4105.12.3.426. View

5.
Fioravanti M, Bianchi V, Cinti M . Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry. 2012; 12:64. PMC: 3528440. DOI: 10.1186/1471-244X-12-64. View